The Importance of the Results of the Phase 3 Trial Assessing Dapagliflozin in Patients With Type 2 Diabetes Hospitalized With COVID-19

Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed why the results of the DARE-19 trial are important to the field, especially during the COVID-19 pandemic.

Pharmacy Times interviewed Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, on the results from the DARE-19 trial assessing the efficacy and safety of dapagliflozin in patients with and without type 2 diabetes hospitalized with COVID-19.

During the discussion, Kosiborod explained why the results of the DARE-19 trial are important to the field, especially during the COVID-19 pandemic.